#Kiriindustries Q3 2022 Concall Highlights

Like & Retweet for better reach !

Operational Highlights

1. The revenues for Q3FY22 stood at ₹429.4Cr from ₹310.3 Cr in same period previous year accounting to growth of 38.4% YoY
2. EBITDA for the quarter stood at ₹48.5Cr translating to EBITDA margins of 11.29%

3. The contributors to Consolidated Net Profit after tax of ₹106.02Crore in Q3-FY22 include share of profit of DyStar (associate company of Kiri) to the tune of ₹81.49 Crore, and
₹13.44Crore from Lonsen Kiri Chemical Industries Limited

3. Consolidated Gross Margin has strengthened to 33%, a Q-o-Q increase of 3% which is further expected to improve in coming quarters
Capacity utilisation
Dyes- 38%, Dye intermediates- 78%, Basic chemicals- 90%, New specialty intermediates (operational from January 21st)- 27%
Vinyl sulfone prices have increased to around ₹380 to ₹390. Maybe shortly it will touch ₹400. The trend is going up.
H-Acid is around ₹475 to ₹485 and expect H-Acid to cross ₹500

- The legal & professional fees, for litigation against Senda and DyStar in Singapore Court(s) which are non-recurring expenditure and exceptional in nature are included in operational expenses
- The company was able to stimulate its business performance in Quarter 3 FY22 due to improved volumes across its diverse product portfolio and also due to fully integrated plants for dyes and 2-stage backward integration of dyes intermediates, specialty
intermediates as well as basic chemicals.

- Kiri experienced a significant increase in power and fuel costs for the second consecutive quarter. With gas prices increasing by 46% and coal prices increasing by around 23% in the current quarter, compared to the previous quarter.
- The rise in coal prices, gas prices, and lignite prices have impacted power and fuel cost, while rising crude oil prices have increased the freight cost.
- The court case is under favour of kiri industries and will evaluate opportunities for settlement in buyout payment or having controlling stake in Dystar
- Hired a few more very senior project people who have joined the project team now. So earlier, it had 3 to 4 people in the project team, now have close to 10 people in project team and some of very senior people from GNFC and other leading companies, who
have years of experience along with young team

- The new upcoming products are specialty intermediates, which are small in quantity for the niche requirement.
There are about 26 products and to be launched one after another, on an annual basis, the first phase is expected to generate around ₹600-₹700 Crs in revenue

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Value Educator

Value Educator Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @ValueEducator

Feb 19
#Rossaribiotech Q3 2022 Concall Highlights

Like & retweet for better reach !

Operational Highlights

1. Revenues for the quarter stood at ₹428.4Cr, up 104% from same period previous year
2. EBITDA stood at ₹46.7 Cr translating to EBITDA margins of 10.9%

3. PAT stood at ₹22.5 Cr with PAT margins of 5.3%

4. Undertaking price hikes wherever possible to offset these raw material pressures.
5. This is the first full quarter of consolidation of recent acquisitions of Unitop and Tristar in Rossari’s performance. Both these companies delivered growth during the period, which assisted overall performance.
Read 14 tweets
Feb 19
#JBChemicals & Pharmaceuticals Q3 FY22 concall highlights 💊💊

Like & Retweet for better reach !

1. They were the fastest growing company among the Top 30 companies in the domestic formulations market as per IQVIA. JB grew at 27% vs market growth of 18%.
2. Revenues for the quarter stood at ₹601 Cr (10% growth YoY).

3. EBITDA excluding ESOP cost stood at ₹153 Cr (10.5% decline YoY). Gross margins for the quarter stood at 66% although there was significant cost inflation.
4. Cost pressure persists on raw material and packing material, which is expected to continue in the medium-term.

5. During Q3 FY22, Domestic Formulations business launched 12 new products including Molnupiravir, Cilacar TM, Azovas-T and Pirfenidone.
Read 12 tweets
Feb 19
#SequentScientific Q3 FY22 concall highlights 🐩🐕‍🦺

Like & Retweet for better reach !

Watch the video to understand the business details :


1. Revenues for the quarter stood at ₹358 Cr (4.8% growth YoY).
2. Growth was mainly driven by the Formulations business which grew at 18.5% YoY on a constant currency basis whereas the API business declined by 20% YoY driven by logistic challenges and subdued demand for Albendazole.
3. Growth in the API portfolio excluding Albendazole has been strong in the first 9 months. Albendazole demand still remains subdued but there is a strong recovery in demand QoQ.
Read 17 tweets
Feb 15
#Nazaratechnologies Q3 2022 Concall Highlights 🎱🎲

Financial Update

1. For Q3FY22 revenue was ₹185.8 Cr vs ₹130.4 Cr in Q3FY21 a growth of 42% on YoY basis.

2. Q3 EBITDA was at ₹30.2 Cr as compared to ₹27.3 Cr in the same quarter of the previous year.
3. For 9M FY22 revenue was ₹446.6 Cr vs ₹330.8 Cr in 9MFY21 a growth of 35% on YoY basis.

4. 9MFY22 EBITDA surged by 141% to ₹79.7 Cr as compared to ₹33.1 Cr in 9MFY21.
5. Esports segment recorded revenue of ₹109.3 Cr in Q3FY22 vs ₹57.8 Cr last year in the same quarter, a growth of 89% YoY basis.
Their Gamified early learning segment recorded revenue of ₹47.2Cr.

6. Freemium segment had revenue of ₹5.7 Cr
Read 16 tweets
Feb 15
#Xelpmoc Q3 2022 Concall highlights

Like & Retweet for better reach !

1. Operating revenue for Q3FY22 was ₹18.3 million compared to ₹11.2 in Q2FY22.

2. Net loss for the Quarter was at ₹29.9 million mainly because of Esop.
3. Portfolio value of investments increased from ₹436.3 million on December 31, 2020 to ₹611.2 million on December 31, 2021.
Business Update

1. Signal Analytics, a wholly owned subsidiary raised ₹52.4 million by way of preferential allotment of Pre Series A. Thereby Xelpmoc shareholding in Signal has changed to 91.95% on a fully diluted basis.
Read 11 tweets
Feb 15
#RateGain Q3 ConCall Highlights

Like & Retweet for better reach !

1. RateGain is a company that provides SaaS solutions to Hotels, travel agencies and Car rentals.

Numbers Update-
1. The revenue for the Quarter was up by 57.4% YoY stood at 99 cr
2. The EBITDA stood at 10.6 cr and the margins were 10.7%

3. PAT margins was 6.3%

4. RateGain has gross margins of 80%

- The company repaid a loan of 900 million rupees to Silicon Bank

- Revenue per employee stands at 6.91 million per employee which is up by 17% YoY
- My Hotel Shop contributed 20 cr of revenue in Q3

- 22% of the revenues are from transactions

- 99.9% revenues of the company are recurring
Read 16 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

:(